Scynexis Inc - Asset Resilience Ratio
Scynexis Inc (SCYX) has an Asset Resilience Ratio of 31.80% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Scynexis Inc debt and liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2014–2024)
This chart shows how Scynexis Inc's Asset Resilience Ratio has changed over time. See SCYX book value for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Scynexis Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market value of Scynexis Inc.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $18.77 Million | 31.8% |
| Total Liquid Assets | $18.77 Million | 31.80% |
Asset Resilience Insights
- Very High Liquidity: Scynexis Inc maintains exceptional liquid asset reserves at 31.80% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Scynexis Inc Industry Peers by Asset Resilience Ratio
Compare Scynexis Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Changchun High & New Technology Industries Group Inc
SHE:000661 |
Drug Manufacturers - Specialty & Generic | 3.73% |
|
Yuhan Corp.
KO:000100 |
Drug Manufacturers - Specialty & Generic | 0.99% |
|
Tasly Pharmaceutical Group Co Ltd
SHG:600535 |
Drug Manufacturers - Specialty & Generic | 9.09% |
|
Zhejiang Hisun Pharmaceutical Co Ltd
SHG:600267 |
Drug Manufacturers - Specialty & Generic | 0.02% |
|
Zhejiang Jiuzhou Pharm Co Ltd
SHG:603456 |
Drug Manufacturers - Specialty & Generic | 0.01% |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091 |
Drug Manufacturers - Specialty & Generic | 26.36% |
|
Jiangsu Kanion Pharmaceutical Co Ltd
SHG:600557 |
Drug Manufacturers - Specialty & Generic | 0.29% |
|
Cronos Group Inc
TO:CRON |
Drug Manufacturers - Specialty & Generic | 69.94% |
Annual Asset Resilience Ratio for Scynexis Inc (2014–2024)
The table below shows the annual Asset Resilience Ratio data for Scynexis Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 47.71% | $43.25 Million | $90.64 Million | +16.32pp |
| 2023-12-31 | 31.39% | $40.31 Million | $128.41 Million | -0.14pp |
| 2022-12-31 | 31.53% | $27.69 Million | $87.81 Million | -- |
| 2021-12-31 | 0.00% | $0.00 | $119.84 Million | -- |
| 2020-12-31 | 0.00% | $0.00 | $102.54 Million | -- |
| 2019-12-31 | 11.36% | $6.49 Million | $57.15 Million | -50.17pp |
| 2018-12-31 | 61.53% | $32.72 Million | $53.17 Million | -9.18pp |
| 2017-12-31 | 70.72% | $32.42 Million | $45.85 Million | +32.37pp |
| 2016-12-31 | 38.35% | $22.93 Million | $59.79 Million | -- |
| 2015-12-31 | 0.00% | $0.00 | $49.27 Million | -- |
| 2014-12-31 | 0.00% | $0.00 | $39.67 Million | -- |
About Scynexis Inc
SCYNEXIS, Inc., a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, a drug for the treatment of invasive candidiasis and/or candidemia, refractory inva… Read more